BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang R, Xu K, Gao F, Huang J, Guan X. Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188590. [PMID: 34271137 DOI: 10.1016/j.bbcan.2021.188590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou M, Ma J, Xu X, Gao X, Wang H, Shen J, Xue L. Candidate oncogene placenta specific 8 affect cell growth and cell migration in non- small cell lung cancers.. [DOI: 10.21203/rs.3.rs-2533161/v1] [Reference Citation Analysis]
2 Liu Z, Zhao Y, Kong P, Liu Y, Huang J, Xu E, Wei W, Li G, Cheng X, Xue L, Li Y, Chen H, Wei S, Sun R, Cui H, Meng Y, Liu M, Li Y, Feng R, Yu X, Zhu R, Wu Y, Li L, Yang B, Ma Y, Wang J, Zhu W, Deng D, Xi Y, Wang F, Li H, Guo S, Zhuang X, Wang X, Jiao Y, Cui Y, Zhan Q. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell 2023;41:181-195.e9. [PMID: 36584672 DOI: 10.1016/j.ccell.2022.12.004] [Reference Citation Analysis]
3 Luo J, Cao D, Hu C, Liang Z, Zhang Y, Lai J. Lymphatic metastasis-associated circRNA‒miRNA‒mRNA network for exploring the pathogenesis and therapeutic target of triple negative breast cancer based on whole-transcriptome sequencing analysis: an experimental verification study. J Transl Med 2022;20:508. [DOI: 10.1186/s12967-022-03728-6] [Reference Citation Analysis]
4 Zhang S, Jiang S, Deng N, Zheng B, Li T, Liu RH. Phytochemical Profiles, Antioxidant Activity and Antiproliferative Mechanism of Rhodiola rosea L. Phenolic Extract. Nutrients 2022;14:3602. [DOI: 10.3390/nu14173602] [Reference Citation Analysis]
5 Chen X, Shu C, Li W, Hou Q, Luo G, Yang K, Wu X. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. J Med Chem 2022. [PMID: 35447031 DOI: 10.1021/acs.jmedchem.2c00063] [Reference Citation Analysis]
6 Peng F, Wang L, Xiong L, Tang H, Du J, Peng C. Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression. Front Pharmacol 2022;13:806869. [DOI: 10.3389/fphar.2022.806869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Jiang ZY, Liu JB, Wang XF, Ma YS, Fu D. Current Status and Prospects of Clinical Treatment of Osteosarcoma. Technol Cancer Res Treat 2022;21:15330338221124696. [PMID: 36128851 DOI: 10.1177/15330338221124696] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Guan X, Wang R. Androgen and Estrogen Receptor Signaling. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00171-1] [Reference Citation Analysis]
9 Telang NT, Nair HB, Wong GYC. Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer. Pharmaceuticals (Basel) 2021;14:1318. [PMID: 34959717 DOI: 10.3390/ph14121318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Li P, Lin Z, Liu Q, Chen S, Gao X, Guo W, Gong F, Wei J, Lin H. Enhancer RNA SLIT2 Inhibits Bone Metastasis of Breast Cancer Through Regulating P38 MAPK/c-Fos Signaling Pathway. Front Oncol 2021;11:743840. [PMID: 34722297 DOI: 10.3389/fonc.2021.743840] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]